Myomo, Inc. (MYO)

Myomo, Inc.'s stock price has significantly declined in the past six months, with the share price dropping from $6.03 on January 31, 2025, to $0.85 as of January 30, 2026. Key events impacting the stock include the Q3 2025 earnings release, which showed decreased gross margins due to a lower average selling price and higher costs. The Q2 2025 earnings release reported increased revenue but lower lead conversion rates and higher operating expenses. An Investor Day revealed challenges in the O&P market and insurance reimbursement, contributing to a stock price drop. The Q1 2025 earnings release reported strong revenue growth driven by Medicare Part B patients, with initial lead generation challenges. The Q4 2024 earnings release included upgraded 2025 guidance and positive news regarding the O&P market, leading to a temporary stock jump.

Myomo, Inc. has indicated that its revenue can be affected by typical seasonality, which is considered in revenue forecasting.

Myomo, Inc. is a commercial-stage medical robotics company focused on providing mobility solutions for individuals with neurological disorders and upper limb paralysis. They operate in the Healthcare sector, specifically the Medical Devices industry, and their main product, MyoPro®, is a non-invasive powered arm brace designed to restore function in paralyzed or weakened arms and hands. MyoPro devices are registered with the FDA as Class II medical devices.

Myomo, Inc. is headquartered in Burlington, Massachusetts, with sales and clinical professionals across the United States. The company has an international presence, delivering MyoPro in Canada and through O&P distribution partners in Europe, particularly in Germany. Myomo also has a growing patient pipeline in Australia and a joint venture to enter the Chinese market in 2021.

Myomo's brand reputation faced challenges in the past year due to lower conversion rates from leads to pipeline additions, particularly from platforms like Facebook. The company has been implementing new marketing strategies, including a program called "MyoConnect," to strengthen relationships with therapists and physicians and reduce reliance on advertising for lead generation.

Myomo, Inc. has substantial institutional ownership, with 53.3% of its shares held by institutions. 120 institutional owners and shareholders hold a total of 15,730,358 shares. Major institutional owners include Rosalind Advisors, Inc., BlackRock, Inc., and Vanguard Group Inc. Paul Gudonis is listed as a significant individual owner.